SORRENTO THERAPEUTICS, INC. Form 8-K (Aug. 11, 2021)

Summary

Current report on Form 8-K for an event dated August 11, 2021, filed by Sorrento Therapeutics, Inc. The report states that on August 11, 2021 the company issued a press release announcing that it has entered into a binding term sheet with Dyadic International, Inc. to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses. The license includes Dyadic's lead COVID-19 vaccine candidate, DYAI-100. The press release is filed as Exhibit 99.1, and Henry Ji signed on August 11, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“SORRENTO THERAPEUTICS, INC. Form 8-K (Aug. 11, 2021).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-8-k-filed2021-08-11-0001104659-21-103236-b903ba5af0/, SHA-256 f66ff6e9ee707b6ca43d80ed0155344283d4a0cdf1045795fbb56de56281347d.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): August 11, 2021

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On August 11, 2021, Sorrento Therapeutics, Inc.
issued a press release announcing that it has entered into a binding term sheet with Dyadic International, Inc. (“Dyadic”)
to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including
Dyadic’s lead COVID-19 vaccine candidate, DYAI-100. A copy of the press release is filed herewith as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

99.1 | Press Release, dated August 11, 2021.
104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: August 11, 2021 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File: SEC_SRNE_8-K_filed2021-08-11_0001104659-21-103236.htm
Size: 24,690 bytes
SHA-256: f66ff6e9ee707b6ca43d80ed0155344283d4a0cdf1045795fbb56de56281347d
Our copy: SEC_SRNE_8-K_filed2021-08-11_0001104659-21-103236.htm
Original: www.sec.gov